OncRef

Clinical Trial: NCT02064387

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:GlaxoSmithKline
Information Provided By:GlaxoSmithKline
Last Update Posted:2020-08-11

Study Overview

Brief Summary

This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA). The hypothesis is that GSK2857916 can be safely administered to subjects with MM and with BCMA positive malignancies at doses where target engagement can be demonstrated. This study will determine if adequate target engagement of BCMA receptors translates into clinical benefit for subjects with MM and BCMA positive lymphomas. The study will consists of two parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safety, tolerability, PK, PD, and clinical activity testing. The study will enroll a total of approximately 80-95 subjects with relapsed/refractory MM or BCMA-expressing hematologic malignancies. The maximum dose to be administered in this trial will not exceed 5 milligram/kilogram(mg/kg).

Official Title

A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

Conditions

Multiple Myeloma

Intervention / Treatment

  • Drug: GSK2857916

Other Study ID Numbers

  • 117159
  • 2013-004549-18

Start Date (Actual)

2014-07-29

Primary Completion Date (Actual)

2018-08-31

Study Completion Date (Actual)

2019-08-01

Enrollment (Actual)

79

Study Type

Interventional

Phase

Phase 1